Xulane Patch
Product Images NDC 50090-1683

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Xulane (NDC 50090-1683). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Vte Risk Of Norelgestromin And Ethinyl Estradiol Transdermal System Relative To Combined Oral Contraceptives (Image 01)

A vertical chart depicting pregnancy rates per 100 women in one year against different contraception methods. It ranges from fewer than 1 pregnancy to 85 or more pregnancies per 100 women, categorizing methods from implants, injections, intrauterine devices, and sterilization at the lowest pregnancy rates to no birth control at the highest. Intermediate methods include birth control pills and skin patches, condoms and diaphragms, and behavioral methods like abstaining during fertile days and use of spermicides or withdrawal.*

FDA Label Image

Figure 5: Mean Serum Concentration-time Profiles Of Ngmn Following Once-daily Administration Of An Oral Contraceptive For Two Cycles Or Application Of Norelgestromin And Ethinyl Estradiol Transdermal System For Two Cycles To The Buttock In Healthy Female Volunteers. [oral Contraceptive: Cycle 2, Days 15 To 21, Norelgestromin And Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] (Image 02)

Four black-and-white photos show a woman applying the XULANE transdermal patch. The patch is demonstrated on the upper arm, lower abdomen, back near the shoulder blade, and outer upper buttock, indicating recommended application sites for the contraceptive patch containing norelgestromin and ethinyl estradiol.*

FDA Label Image

Image 03

An instructional illustration showing hands peeling open a foil pouch to remove a transdermal patch. The image demonstrates the proper method to open the packaging containing the XULANE patch, a human prescription drug containing norelgestromin and ethinyl estradiol.*

FDA Label Image

Figure 6: Mean Serum Concentration-time Profiles Of Ee Following Once-daily Administration Of An Oral Contraceptive For Two Cycles Or Application Of Norelgestromin And Ethinyl Estradiol Transdermal System For Two Cycles To The Buttock In Healthy Female Volunteers. [oral Contraceptive: Cycle 2, Days 15 To 21, Norelgestromin And Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] (Image 04)

An instructional illustration showing hands demonstrating how to apply a XULANE transdermal patch. One hand holds the patch while the other is peeling off a protective liner, indicating preparation for transdermal application.*

FDA Label Image

Norelgestromin And Ethinyl Estradiol Structural Formulas (Image 05)

An instructional photo showing hands applying a rectangular transdermal patch, identified as XULANE, on the skin. The patch is smooth, white or off-white, and positioned on the abdomen area. This demonstrates the proper usage of the XULANE patch, which contains norelgestromin and ethinyl estradiol for transdermal delivery.*

FDA Label Image

Image 06

An illustration showing hands applying the XULANE transdermal patch to the lower abdomen area of the body. The patch is a square adhesive medication device intended for transdermal delivery of norelgestromin and ethinyl estradiol.*

FDA Label Image

Image 07

A horizontal bar chart comparing the number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC User Non-Pregnant, CHC User, Pregnancy, and Postpartum (12 weeks only). The chart shows ranges from 1 to 5, 3 to 12, 5 to 20, and 40 to 65 respectively, with a note defining CHC as combination hormonal contraception and pregnancy data based on reference study durations.*

FDA Label Image

Image 08

Chemical structure diagrams of the active ingredients norelgestromin and ethinyl estradiol shown side by side, as part of XULANE's product labeling.*

FDA Label Image

Image 09

A line graph showing the concentration of NGMN (ng/mL) over time (hours) across different cycles and weeks (Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, Cycle 3 Week 3). The graph depicts the changes in NGMN concentration in the blood during and after transdermal patch application of XULANE, with peak concentrations reached between 24 and 96 hours, followed by a decline to near baseline by 168-240 hours.*

FDA Label Image

Image 10

A line graph depicting ethinyl estradiol (EE) concentration in pg/mL over time in hours (h). The graph compares EE levels for Cycle 1 Week 1 and Cycle 3 Weeks 1 and 3, showing changes in concentration from 0 to 240 hours, with distinct lines and markers for each time point.*

FDA Label Image

Image 11

A pharmacokinetic graph showing norelgestromin (NGMN) concentration in ng/mL over time in hours, comparing a transdermal system applied to the buttock with an oral contraceptive containing NGM 250 µg and EE 35 µg. The graph plots steady state concentration data over 240 hours.*

FDA Label Image

Image 12

A line graph depicting ethinyl estradiol (EE) concentration (pg/mL) over time (hours) comparing a norelgestromin and ethinyl estradiol transdermal patch applied to the buttock versus an oral contraceptive with 250 µg norelgestromin and 35 µg EE, including estimated steady state data based on day 21. The graph shows concentration trends over 240 hours.*

FDA Label Image

Image 14

A calendar chart illustrating the schedule for applying XULANE transdermal patches over four weeks. Patches are indicated for the first three weeks (Day 1, Day 8, Day 15), with an arrow marking each week, and a marked note *

FDA Label Image

Image 15

A horizontal bar chart comparing the number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women within 12 weeks. Each bar indicates the range of blood clot cases, with postpartum women showing the highest range and Non-CHC non-pregnant users the lowest. A footnote explains CHC as combination hormonal contraception and details pregnancy data assumptions.*

FDA Label Image

Image 16

Illustration showing a person using their hands to open a foil pouch containing a transdermal patch. The image likely demonstrates the initial steps in handling or applying the XULANE patch, which delivers norelgestromin and ethinyl estradiol.*

FDA Label Image

Image 17

An instructional illustration labeled 'Figure B' showing a hand holding a square adhesive patch, demonstrating proper handling of the patch for application.*

FDA Label Image

Image 18

A series of four black-and-white photographs showing proper placement of XULANE transdermal patches on a female body. The patches are demonstrated adhered to the upper arm, lower abdomen, upper buttock, and upper back, illustrating recommended application sites for the norelgestromin and ethinyl estradiol patch.*

FDA Label Image

Image 19

An instructional illustration showing two hands peeling back the protective foil packaging of a XULANE transdermal patch, revealing the adhesive side for application. The image demonstrates the step of removing and preparing the norelgestromin and ethinyl estradiol 150; 35 ug/d patch for use.*

FDA Label Image

Image 20

An instructional illustration showing a person applying a XULANE patch. The image focuses on hands holding the transdermal patch, demonstrating the correct method of application for the contraceptive patch containing norelgestromin and ethinyl estradiol.*

FDA Label Image

Image 21

An illustration showing hands applying a XULANE transdermal patch to the skin on the abdomen. The patch is rectangular and is being positioned on the skin as part of the designated usage instructions for this norelgestromin and ethinyl estradiol hormonal contraceptive patch.*

FDA Label Image

Image 22

An illustration showing hands applying a transdermal patch, identified as XULANE, to the abdominal skin. The patch is square and positioned just below the navel, aligned to adhere flat against the skin. The image demonstrates correct placement for the norelgestromin and ethinyl estradiol contraceptive patch.*

FDA Label Image

Label Image (Lbl500901683)

XULANE transdermal patch label showing strength of 150/35 MCG per day of norelgestromin and ethinyl estradiol. Label includes NDC 50090-1683-0, manufacturer A-S Medication Solutions, and storage instructions to keep at 68 to 77 degrees Fahrenheit. The package contains three transdermal systems.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.